THE TREATMENT OF OSTEOCHONDRAL DEFECTS WITH OSTEOCHONDRAL AUTOLOGOUS CYLINDER TRANSPLANTATION

Abstract

Osteochondral autologous transplantation (OATS) is a new technique for the treatment of osteochondral defects.

In a prospective randomised study, between November 1996 and June 2000 we used the OATS technique to treat 136 patients (90 male, 46 female) with a mean osteochondral defect of 3.3 cm2. The defect was in the medial femoral condyle in 54 cases, the lateral femoral condyle in nine, the patella in 15, the trochlea in six, the tibial plateau in one, the talus in 29, the tibial plafond in two, the capitellum in four. There were 16 other locations. The procedure was performed either open or arthroscopically. A mean of 2.2 cylinders was transplanted. At the same time, we treated malalignment by high tibial osteotomy (HTO) in 20 patients, and instability by anterior (ACL) or posterior cruciate ligament (PCL) reconstruction in 16. Five patients required reconstruction of both ACL and PCL.

The Lysholm score in the lower limbs increased from a preoperative mean of 58.3 (20 to 77) to a mean of 90.2 (70 to 100). Treatment by OATS alone increased the score from 62.9 to 91.6. The combination of OATS and HTO increased the score from 65.2 to 91.6. With additional ACL/PCL reconstruction, the score increased from 49.9 to 82.6. The combination of OATS, HTO and ACL/PCL reconstruction increased the Lysholm score from 55.5 to 85.5. Control postoperative MRI with IV contrast (Gd-DTPA) showed incorporation of all but one cylinder. Complications included one case of arthrofibrosis and sinking of one cylinder. One patient developed regional pain syndrome and three had pain at the malleolar osteotomy site, resolved by screw removal. For four weeks after the operation, 10% of patients complained of pain at the donor side in the lateral femoral condyle. There were no complications related to OATS performed in the upper limbs, and control MRI three months postoperatively showed incorporation of all cylinders.

The results are encouraging, and give rise to the hope that this cost-effective and safe new treatment for limited osteochondral defects may delay or even prevent the onset of osteoarthritis.